- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05854966
CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
An Open Label, Pilot Phase II Study to Evaluate the Feasibility and Efficacy of CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary Objective: To establish the feasibility of delivering the combination of CPI-613 and metformin in patients with relapsed or refractory acute myeloid leukemia (AML).
Secondary Objectives: To determine the response rate of CPI-613 and metformin in relapsed or refractory AML defined as Complete remission (CR) + Complete remission with incomplete count recovery (CRi) + Morphologic Leukemia-Free State (MLFS).
- To determine the overall survival of patients with relapsed or refractory AML treated with CPI-613 and metformin.
- To determine the safety of CPI-613 and metformin in patients with relapsed or refractory acute myeloid leukemia (AML).
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Study Coodinator
- Phone Number: 336-716-5440
- Email: bpowell@wakehealth.edu
Study Locations
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest Baptist Comprehensive Cancer Center
-
Contact:
- Study Coordinator
- Phone Number: 336-716-5440
- Email: bpowell@wakehealth.edu
-
Principal Investigator:
- Bayard Powell, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients must have histologically or cytologically documented relapsed and/or refractory Acute Myeloid Leukemia or granulocytic sarcoma.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 3.
- Must be ≥ 18 years of age.
- Persons of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use accepted contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive or double barrier device), and must have a negative serum or urine pregnancy test within 1 week prior to treatment initiation.
- Persons who are having sexual relationships in which their partner may become pregnant must practice effective contraceptive methods during the study treatment and for 60 days after the last dose of study treatment, unless documentation of infertility exists.
- Mentally competent, ability to understand and willingness to sign the informed consent form.
- Patients with persisting, non-hematologic, non-infectious toxicities from prior treatment must be ≤ Grade 2 and must be documented as such.
- Laboratory values ≤ 2 weeks prior to the start of study treatment must be the following:
- Aspartate aminotransferase [AST/SGOT] ≤ 5x upper normal limit [UNL],
- Alanine aminotransferase [ALT/SGPT] ≤ 5x UNL
- Bilirubin ≤ 3x UNL
- Albumin ≥ 2.0 g/dL or ≥ 20 g/L
- Serum creatinine ≤ 2.0 mg/dL
- Presence of central venous catheter or willing to have central venous access placed.
Exclusion Criteria:
- Patients with active central nervous system (CNS) or epidural tumor.
- Pregnant persons, or persons of child-bearing potential not using reliable means of contraception (because the teratogenic potential of CPI-613 is unknown).
- Breastfeeding individuals because the potential of excretion of CPI-613 into breast milk. (Note: Breastfeeding individuals are excluded because the effects of CPI-613 on a nursing child are unknown).
- Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of patient.
- Unwilling or unable to follow protocol requirements.
- Patients receiving any other standard or investigational treatment for their cancer, or any other investigational agent for any indication within the past 1 week prior to initiation of CPI-613 treatment with the following exceptions:
- The use of Hydrea or any targeted oral agent is allowed up to the day before initiation of treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment - CPI-613 with Metformin
Induction therapy with CPI-613 and Metformin (ideally 2 hours prior to start of CPI-613 infusions on days 1-5) for two cycles of treatment. Maintenance therapy with CPI-613 and Metformin (ideally 2 hours prior to start of CPI-613 infusions on days 1-5) until progression, intolerable toxicity of withdrawal of consent. |
For INDUCTION therapy (14 day cycles): Devimistat (CPI-613) 2,500mg/m2, days 1-5, 14-day cycles for cycles 1 and 2 only. For MAINTENANCE therapy (21 day cycles): Devimistat (CPI-613) 2,500mg/m2, days 1-5, 21-day cycles until progression, intolerable toxicity or withdrawal of consent.
Other Names:
For INDUCTION therapy (14 day cycles): Metformin 500 mg daily (taken with meals), days 1-2 for cycle 1 only. Metformin 500 mg twice daily (taken with meals), days 3-14 for cycle 1 only. Metformin 1,000 mg daily (taken with meals), days 1-2 for cycle 2 only. Metformin 1,000 mg twice daily (taken with meals) days 3-4 for cycle 2 only. For MAINTENANCE therapy (21 day cycles): Metformin 1,000 mg twice daily (taken with meals) days 1-21 until progression, intolerable toxicity or withdrawal of consent
Other Names:
In the first induction cycle ONLY, extra blood will be withdrawn on day 1 before and after treatment with CPI-613 research purposes.
Additional blood draws on days 2-5 to test blood before receiving CPI-613 to make sure participants are healthy enough to receive CPI-613.
After the second induction cycle participants will have a bone marrow biopsy.
After this biopsy, participants will have other bone marrow biopsies every 3 months for the next year.
After the first year, participants may have a bone marrow biopsy if the treating physician feels it is necessary.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants to Receive at Least One Cycle of Maintenance Therapy - Feasibility
Time Frame: After the completion of cycle 1 of maintenance therapy (maintenance cycle is 21 days)
|
Feasibility is defined as the ability to deliver at least 1 cycle of maintenance therapy in 50% or more of patients who complete induction therapy.
|
After the completion of cycle 1 of maintenance therapy (maintenance cycle is 21 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response Rate - Efficacy (Acute Myeloid Leukemia European LeukemiaNet 2022)
Time Frame: After the completion of cycle 2 (each cycle is 14 days), then every three months up to 12 months
|
Efficacy will be assessed in the first 9 evaluable participants using a Simon's two-stage design to examine efficacy in terms of response where response is defined as:
|
After the completion of cycle 2 (each cycle is 14 days), then every three months up to 12 months
|
Overall Survival
Time Frame: Every 3 months after last dose of study treatment, up to 2 years
|
Overall survival is calculated in days from date of study treatment initiation to date of death due to any cause.
Patients last known to be alive are censored at date of last contact.
|
Every 3 months after last dose of study treatment, up to 2 years
|
Number of Reported Adverse Events - Safety
Time Frame: Up to 30 days after last dose of study treatment
|
Safety will be evaluated by describing the nature and frequency of adverse events as defined by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
|
Up to 30 days after last dose of study treatment
|
Collaborators and Investigators
Investigators
- Principal Investigator: Bayard Powell, MD, Wake Forest Baptist Comprehensive Cancer Center
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- WFBCCC 22323
- P30CA012197 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia, in Relapse
-
University of FreiburgCompletedAcute Myeloid Leukemia, in RelapseGermany
-
St. Jude Children's Research HospitalAbbVie; Gateway for Cancer Research; Karyopharm Therapeutics IncRecruitingRefractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse | Acute Leukemia of Ambiguous Lineage in Relapse | Refractory Acute Leukemia of Ambiguous LineageUnited States
-
UNC Lineberger Comprehensive Cancer CenterMerck Sharp & Dohme LLCActive, not recruitingAcute Myeloid Leukemia, in RelapseUnited States
-
All India Institute of Medical Sciences, New DelhiUnknown
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory | Relapsed Acute Myeloid LeukemiaUnited States
-
Peking University People's HospitalBeijing JD Biotech Co. LTD.RecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryChina
-
Xuzhou Medical UniversityRecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryChina
-
Bio-Path Holdings, Inc.RecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryUnited States
-
Xuzhou Medical UniversityRecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryChina
Clinical Trials on CPI 613
-
Wake Forest University Health SciencesCompleted
-
Cornerstone PharmaceuticalsCompletedLymphoma | Metastatic Cancer | Advanced Cancer | Solid Tumors | Advanced MalignanciesUnited States, Canada
-
Memorial Sloan Kettering Cancer CenterM.D. Anderson Cancer Center; Massachusetts General Hospital; City of Hope Medical... and other collaboratorsActive, not recruiting
-
Medical College of WisconsinBarbara Ann Karmanos Cancer Institute; Cornerstone PharmaceuticalsRecruitingPancreas AdenocarcinomaUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Cornerstone PharmaceuticalsWithdrawnPancreatic Ductal Adenocarcinoma
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedAdvanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Recurrent Extrahepatic Bile Duct Cancer | Unresectable Extrahepatic Bile Duct Cancer | Cholangiocarcinoma of the Extrahepatic Bile Duct | Cholangiocarcinoma of the Gallbladder and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)WithdrawnStage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7United States
-
Cornerstone PharmaceuticalsWithdrawnAcute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)United States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)TerminatedPreviously Treated Myelodysplastic SyndromesUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedRecurrent Small Cell Lung CancerUnited States